NCT02546531View on ClinicalTrials.gov

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 3, 2016

Primary Completion Date

November 17, 2017

Study Completion Date

January 11, 2021

Conditions
Advanced Solid TumorsSolid TumorsPancreatic Cancer
Interventions
BIOLOGICAL

Defactinib

BIOLOGICAL

Pembrolizumab

DRUG

Gemcitabine

Trial Locations (2)

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

The Foundation for Barnes-Jewish Hospital

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Verastem, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02546531 - Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter